Jean-­Marc Ferrero

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Sandra M. Swain, Sung‐Bae Kim, Javier Cortés et al. · The Lancet Oncology · 2013 · 985 citations · Full text

Breast Oncology, Medicine, Cleopatra Study +7

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology · 2012 · 733 citations

Breast Oncology, Brain Metastases, Medicine +8

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

Thomas Bachelot, C. Bourgier, Claire Cropet et al. · Journal of Clinical Oncology · 2012 · 707 citations · Full text